SynAct Pharma AB (publ) (“SynAct”) hereby publishes the memorandum on the occasion of the company’s rights issue, the subscription period for which begins on 19th April 2018. The memorandum is available at the company’s(www.synactpharma.com), AktieTorget’s (www.aktietorget.se) and Sedermera Fondkommission’s (www.sedermera.se) respective websites. Teaser and application form without preferential rights will be published on the above-mentioned websites when the subscription period starts.
Memorandum, teaser and application form
The memorandum for the rights issue is now published at Synact Pharma’s, AktieTorget’s and Sedermera Fondkommission’s respective websites (www.synactpharma.com, www.aktietorget.se and www.sedermera.se). The teaser and application form without preferential rights will be published on the above-mentioned websites when the subscription period starts.
The offer in brief
| Preferential rights and record date: | The last day of trading in SynAct Pharma’s shares including the right to receive subscription rights is 11th April 2018 and the first day excluding the right to receive subscription rights is 12th April 2018. The record date is 13th April 2018. One (1) subscription right can be redeemed for each existing share. Possession of eleven (11) subscription rights entitles the holder to subscribe to two (2) new shares. |
| Subscription period: | 19th April – 8th May 2018. |
| Subscription price: | SEK 9.90 per share. |
| Size of issue : | The offer comprises a maximum of 2,257,718 shares, equivalent to SEK 22,351,408.20. The public is also given the opportunity to subscribe for shares in the rights issue. |
| Number of shares before new issue: | 12, 417,449 shares. |
| Pre-money valuation: | Approximately SEK 123 million. |
| Trading in subscription rights: | Trading in subscription rights will take place on AktieTorget between 19th April 2018 and 4th May 2018. |
| Trading in BTA: | Trading in BTA (Betald Tecknad Aktie – Paid subscribed shares) will take place on Aktietorget from 19 April 2018 until the new share issue has been registered with the Swedish Companies Registration Office. This registration is estimated to take place at the end of May 2018. |
| Subscription commitments | The company has received subscription commitments totalling approximately SEK 9.1 million, totalling approximately 41 percent of the issue volume. |
| Marketplace: | SynAct’s shares are quoted on AktieTorget. |
Financial advisor
Sedermera Fondkommission is the financial advisor and acting issuer agent for SynAct Pharma in connection with the rights issue.
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Telephone: +45 28 44 75 67
E-mail: [email protected]
Thomas Jonassen
CSO, SynAct Pharma AB
Telephone: +45 40 15 66 69
E-mail: tj@synactpharma.com